PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

An expert discusses the design and objectives of the PEACE-3 study, which investigates the combination of enzalutamide and radium-223 for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).

EP: 1.Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP: 2.Therapeutic options for a patient with mCRPC after ADT + docetaxel

Now Viewing

EP: 3.PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

EP: 4.PEACE-3 Study Results: Study Population & Disposition

Recent Videos